NY-ULTIVUE
7.4.2022 16:02:08 CEST | Business Wire | Press release
Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige , the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers.
Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels.
The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus™, an intuitive and responsive viewer for pathology scans that supports primary diagnosis together with a data management solution for storage of pathology scans. The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
“This collaboration with Paige is an exciting milestone for Ultivue as we consider the evolving impact of AI and deep learning tools on histopathological images in clinical settings,” said Jacques Corriveau, CEO, Ultivue. “Importantly, our aligned goals are to facilitate the decentralization and democratization of the generation and analysis of complex spatial data.”
“The combination of Ultivue’s robust biomarker detection capabilities and Paige’s AI-enabled computational pathology technology allows us to deliver new products that will elevate how immuno-oncology research is done today,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions.”
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product. For additional information, please visit: paige.ai , Twitter and LinkedIn .
About Ultivue
Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005283/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Acquisition brings together two highly complementary, science-backed skincare brands ZO Skin Health’s premium daily multi-step regimens complement Alastin’s regenerative skincare portfolio primarily focused on peri-procedure support Transaction expands Galderma’s Dermatological Skincare portfolio and offering in the attractive, fast-growing physician-dispensed skincare segment1 Galderma’s unique Integrated Dermatology Strategy, global scale and omni-channel execution capabilities expected to support ZO Skin Health’s next phase of growth Acquisition of 100% of ZO Skin Health for an enterprise value of 1.5 billion USD, expected to be Core EPS neutral in the first full year following closing Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone
Pretium Expands Middle East Presence with Abu Dhabi Office14.10.2026 06:02:00 CEST | Press release
Office will enable Pretium to engage more directly with institutional partners across the Middle East Pretium, a specialized investment firm with approximately $70 billion in assets under management1, today announced the opening of an office in Abu Dhabi. The office will operate within Abu Dhabi Global Market (“ADGM”), the international financial center of Abu Dhabi, providing proximity to some of the world’s leading institutional investors. The Abu Dhabi office marks an important step in the continued evolution of Pretium’s business. From its roots in U.S. residential real estate, Pretium has built a scaled investment platform spanning real estate equity and credit. A dedicated presence in Abu Dhabi will enhance the Firm’s connections to clients in the region as it continues to develop new investment solutions. “Abu Dhabi is home to some of the world’s most sophisticated and forward-looking institutional investors,” said Don Mullen, Founder and CEO of Pretium. “An on-the-ground presen
IFF to Release Third Quarter 2026 Results on November 3, 202613.10.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that it will release its third quarter 2026 earnings results following the market close on Tuesday, November 3, 2026. The management team will host a live webcast on Wednesday, November 4, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, and health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire
Industry Leaders Formally Launch SCMP OCP Workstream for Open, Secure AI Infrastructure Management and Control13.10.2026 19:15:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, and AMI, a Lattice company, today announced SCMP (Secure Control and Management Plane), a new Open Compute Project workstream. Announced during a joint keynote at the 2026 OCP Global Summit, SCMP is an open, vendor-neutral architecture for secure control, boot, and management of data center infrastructure. It gives data center operators more confidence that complex AI systems will work as expected across vendors and platforms, with less integration risk and more freedom of choice. SCMP defines how a control authority establishes and maintains trust from silicon root of trust through rack and pod, building on existing OCP initiatives and industry standards. “As AI infrastructure scales toward autonomous operation, the management and control plane becomes the foundation of trust. That foundation should be open and verifiable, and SCMP gives the industry a common architecture to achieve it, from
Saudi Fund for Development Announces Progress on Pristina–Mitrovica Highway Project in Kosovo13.10.2026 15:36:00 CEST | Press release
The Saudi Fund for Development (SFD) today joined the Government of Kosovo to inaugurate the Pristina–Mitrovica Highway, marking SFD’s first completed project in Kosovo and an important milestone in the partnership between both sides. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013433726/en/ SFD CEO and Kosovar's minsters sideline meeting (Photo: AETOSWire) His Excellency Sultan bin Abdulrahman Al-Marshad, Chief Executive Officer of the Saudi Fund for Development, inaugurated the upgraded highway section by cutting the ribbon at the newly completed road. He subsequently held a sideline meetings with His Excellency Hekuran Murati, Minister of Finance, His Excellency Dimal Basha Minister of Infrastructure and Transport, and His Excellency Arben Vitia, Minister of Health, to discuss the development projects and the continued SFD- Kosovo partnership. The project upgrades a 9.87 km section of the Prishtina–Mitrovica Highway
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom